Friday, May 26, 2023 Daily Archives

Touchlight takes derelict building to DNA plant

by

Enzymatic DNA manufacturer Touchlight has repurposed a derelict waterworks in London, UK and redeveloped it into a DNA production facility. While it is not common practice that a Victorian derelict waterworks located near to the River Thames in Hampton, London is repurposed into a DNA manufacturing plant, CEO of Touchlight, Karen Fallen told BioProcess Insider “this was a unique option presented to us, and we didn’t want to pass on the opportunity to be situated in such an attractive location.”…

May 26, 2023

What comes after mRNA? Self-amplified RNA, states industry report

by

As firms look beyond COVID-19, one of the most promising platforms is self-amplifying RNAs, says a report from Clarivate. The report by Clarivate, entitled “Where pharma are investing for the future of medicine”, said messenger RNA (mRNA) COVID-19 vaccines demonstrated “proof of concept for the technology” with BioNTech/Pfizer and Moderna releasing their  respective COVID-19 vaccines in 2020 and 2021. As life returns to normal, pandemic-related orders for COVID-19 vaccines have dropped in size –  Pfizer, for example, reported a 26%…

May 26, 2023

FDA delays Sarepta DMD gene therapy decision

by

Sarepta Therapeutics says the US FDA needs additional time to review Duchenne muscular dystrophy (DMD) gene therapy delandistrogene moxeparvovec (SRP-9001). In November 2022, the US Food and Drug Administration (FDA) accepted the submission from Sarepta for its potential DMD gene therapy SRP-9001. The Agency initially provided the firm with an action date of May 29, 2023; however, this has now been delayed until June 22, 2023. The additional time requested by the FDA to complete the review will also include…

May 26, 2023